Tough Cell to Investors.

Observes that while stem cells have the potential to provide therapies for a vast range of ills, it is proving hard to attract the investment needed to develop them. Reasons why venture capitalists are hesitant to invest in stem cell research; How a lack of basic research creates a major risk; Views of Brian Kerr, director at Scottish Equity Partners, who says public markets continue to shun biotechnology companies; Investments in Australia, where a number of stem cell companies have listed on the Australian Stock Exchange; How market fragmentation is making stem cells a difficult business for big pharmaceutical companies; Ethical and regulatory issues.